Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME G DEVILLE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1750301503
CMS profile
306772
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$119.70

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $119.70 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $119.70 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME G DEVILLE

NPI 1750301503 · CMS profile ID 306772

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $119.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $119.7010/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671586299 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $119.70 1
PY2023 $12,707.12 13
PY2024 $184.08 4
PY2025 $2,569.53 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,582.34 15
PY2025 Principal investigator $260,502.25 43
PY2024 Principal investigator $147,535.10 28
PY2023 Recipient $2,359.23 6
PY2023 Principal investigator $286,959.88 51
PY2022 Principal investigator $147,785.97 35
PY2021 Recipient $31,165.00 1
PY2021 Principal investigator $320,361.44 168
PY2020 Principal investigator $484,980.10 158
PY2019 Principal investigator $153,612.59 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

158 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $7,228.00 12/23/2020 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 742075997
Principal investigator 1 Gilead Sciences, Inc. $1,575.00 12/02/2020 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 742075995
Principal investigator 1 Astellas Pharma Global Development $154,724.00 11/05/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 721320657
Principal investigator 1 Gilead Sciences, Inc. $7,971.00 10/21/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 742079225
Principal investigator 1 Merck Sharp & Dohme Corporation $103.32 10/20/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA NICHD CRS
IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission A Phase I,II Proof of Concept Study No dispute reported 06/30/2026 740702215
Principal investigator 1 Merck Sharp & Dohme Corporation $413.28 10/20/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA NICHD CRS
IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission A Phase I,II Proof of Concept Study No dispute reported 06/30/2026 740702217
Principal investigator 1 Gilead Sciences, Inc. $28,663.00 10/12/2020 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 742075993
Principal investigator 1 Gilead Sciences, Inc. $21,105.00 08/24/2020 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 742075991
Principal investigator 1 Astellas US Technologies $315.39 08/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604291
Principal investigator 1 Astellas US Technologies $315.39 08/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604295
Principal investigator 1 Astellas US Technologies $315.39 08/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604299
Principal investigator 1 Astellas US Technologies $315.39 08/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604303
Principal investigator 1 Astellas US Technologies $315.39 08/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604307
Principal investigator 1 ViiV Healthcare Company $1,179.66 08/11/2020 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 733426616
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604229
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604233
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604239
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604243
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604247
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604250
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604254
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604259
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604263
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604266
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604269
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604273
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604277
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604281
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604285
Principal investigator 1 Astellas US Technologies $315.39 07/24/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604289
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604191
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604195
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604199
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604201
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604205
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604209
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604213
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604215
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604219
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604223
Principal investigator 1 Astellas US Technologies $315.39 07/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604227
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604137
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604141
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604143
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604147
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604151
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604155
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604158
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604161
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604167
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604171
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604175
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604179
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604181
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604185
Principal investigator 1 Astellas US Technologies $315.39 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604189
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $6,300.00 06/23/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 748315761
Principal investigator 1 Gilead Sciences, Inc. $1,560.00 06/17/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 742079223
Principal investigator 1 Astellas Pharma Global Development $173,899.00 06/11/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 721320625
Principal investigator 1 Gilead Sciences, Inc. $1,560.00 04/27/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 742079221
Principal investigator 1 Astellas Pharma Global Development $7,475.00 04/14/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 721320613
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $2,142.00 04/07/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 748315759
Principal investigator 1 ViiV Healthcare Company $1,688.49 04/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 733423855
Principal investigator 1 ViiV Healthcare Company $3,780.00 04/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 733423849
Principal investigator 1 Gilead Sciences, Inc. $4,737.00 03/18/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 742079219
Principal investigator 1 ViiV Healthcare Company $2,359.31 03/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 733423845
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604069
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604073
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604077
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604079
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604081
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604085
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604087
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604091
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604093
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604097
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604101
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604103
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604107
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604111
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604115
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604119
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604121
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604125
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604129
Principal investigator 1 Astellas US Technologies $315.39 02/28/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604133
Principal investigator 1 Gilead Sciences, Inc. $7,857.00 02/24/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 742079217
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603993
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603997
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604001
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604005
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604009
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604013
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604017
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604019
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604023
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604027
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604031
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604033
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604037
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604041
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604043
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604045
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604049
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604053
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604057
Principal investigator 1 Astellas US Technologies $315.39 02/19/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604061
Principal investigator 1 Astellas Pharma Global Development $1,030.00 02/13/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 721320603
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603937
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603939
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603943
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603949
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603951
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603955
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603959
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603963
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603967
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603971
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603977
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603979
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603983
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603987
Principal investigator 1 Astellas US Technologies $315.39 02/10/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603989
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603870
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603875
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603883
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603887
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603889
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603891
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603895
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603897
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603901
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603905
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603907
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603911
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603915
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603917
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603921
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603925
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603930
Principal investigator 1 Astellas US Technologies $315.39 02/06/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603935
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603811
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603815
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603819
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603821
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603825
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603829
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603833
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603837
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603841
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603845
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603849
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603851
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603856
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603859
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603861
Principal investigator 1 Astellas US Technologies $315.39 01/31/2020 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709603867
Principal investigator 1 Gilead Sciences, Inc. $4,737.00 01/27/2020 Non-covered Recipient Entity
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 742079215